



23 April 2009

Darren Collins
Senior Adviser, Issuers and Accounting Policy
ASX Markets Supervision Pty Ltd
Level 45
South Tower
525 Collins Street
MELBOURNE VIC 3000

Dear Darren

**Sun Biomedical Limited (the “Company”)
Price Query**


We refer to your letter of 22 April 2009 in relation to a recent increase in the price of the Company’s securities and trading volumes.

We respond to your queries as follows:

1. The Company is not aware of any information concerning it that has not previously been announced which, if known, could be an explanation for recent trading in the securities of the Company.
2. Not applicable.
3. As previously announced, the Company's search for a strategic partner has not resulted in any suitable offers and it now intends to seek offers for its patents. The value of these patents cannot be accurately determined and may therefore result in a write down in the current financial year. At this stage, the Company does not anticipate that there will be a variation of more than 15% from the operating loss recorded in the previous corresponding period.

4. The Company provided an update on its search for a strategic partner in respect of its US Subsidiary, Sun Biomedical Laboratories Inc on 17 April 2009 and the Company is not aware of any information concerning it that has not been announced.
5. The Company is not aware of any other explanation for the price volume increases.
6. As far as the Company is aware, it is in compliance with all ASX Listing Rules, including Listing Rule 3.1.

Yours faithfully

A handwritten signature in black ink, appearing to read 'Alfonso Grillo', is written over a faint, light-colored rectangular stamp or watermark.

Alfonso Grillo
Company Secretary



ASX Markets Supervision Pty
Ltd
ABN 26 087 780 489
Level 45
South Tower
525 Collins Street
Melbourne VIC 3000
GPO Box 1784
Melbourne VIC 3001
Telephone 61 3 9617 8656
Facsimile 61 3 9614 0303
www.asx.com.au

22 April 2009

Mr Alfonso Grillo
Company Secretary
Sun Biomedical Limited
TressCox Lawyers
Level 9, 469 La Trobe Street
MELBOURNE VIC 3004

By e-mail only

Dear Alfonso

Sun Biomedical Limited (the "Company") RE: PRICE QUERY

We have noted a change in the price of the Company's securities from 0.2 cents at commencement of trading to 0.4 cents at close of trading today. We have also observed larger than normal volumes of trades during this period.

In light of the price change and increase in trading volumes, please respond to each of the following questions.

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?

Please note that as recent trading in the Company's securities could indicate that information has ceased to be confidential, the Company is unable to rely on the exceptions to listing rule 3.1 contained in listing rule 3.1A when answering this question.

2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be made immediately, you need to contact us to discuss this and you need to consider a trading halt (see below).

3. Is there any reason to think that there may be a change in the operating loss before abnormal items and income tax so that the figure for the financial year ended 30 June 2009 would vary from the previous corresponding period by more than 15%? If so, please provide details as to the extent of the likely variation.

4. Is there any reason to think that the Company may record any material abnormal or extraordinary item for the financial year ended 30 June 2009? If so, please provide details.

5. Is there any other explanation that the Company may have for the price change and increase in volume in the securities of the Company?
6. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.

Your response should be sent to me by e-mail at darren.collins@asx.com.au or by facsimile on facsimile number 9614 0303. It should not be sent to the Company Announcements Office.

Unless the information is required immediately under listing rule 3.1, a response is requested as soon as possible and, in any event, not later than half an hour before the start of trading (i.e. before 9.30 a.m. EST) on Thursday 23 April 2009.

Under listing rule 18.7A, a copy of this query and your response will be released to the market, so your response should be in a suitable form and separately address each of the questions asked. If you have any queries or concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. The exceptions to this requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance Note 8 – Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given to ASX under listing rule 3.1 your obligation is to disclose the information immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to question 1 is yes and an announcement cannot be made immediately, you should consider a request for a trading halt in the 's securities. As set out in listing rule 17.1 and Guidance Note 16 – Trading Halts, we may grant a trading halt at your request. We may require the request to be in writing. We are not required to act on your request. You must tell us each of the following.

- The reasons for the trading halt.
- How long you want the trading halt to last.
- The event you expect to happen that will end the trading halt.
- That you are not aware of any reason why the trading halt should not be granted.
- Any other information necessary to inform the market about the trading halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. If a trading halt is requested and granted and you are still unable to reply to this letter before the commencement of trading, suspension from quotation would normally be imposed by us from the commencement of trading if not previously requested by you. The same applies if you have requested a trading halt because you are unable to release information to the market, and are still unable to do so before the commencement of trading.

If you have any queries regarding any of the above, please let me know.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Darren Collins', with a stylized, cursive script.

Darren Collins

Senior Adviser, Issuers and Accounting Policy